Product: Anti-MADD (C-terminus), Polyclonal
Cat. No: PC-023 (100 μg)
Background:
MAP kinase-activating death domain protein
(MADD) was initially identified as the type 1
tumor necrosis factor receptor (TNFR1)
associated protein though their death domains
(1). Overexpression of MADD activates MAP
kinases ERK and JNK and induces the
phosphorylation of cytosolic phospholipase A2
(1). MADD shares 98 identity with DENN (for
differentially expressed in neoplastic vs. normal
cells), which was recently identified as a
substrate for c-jun N-terminal kinase 3 (JNK3) (2,
3). MADD has greater than 94 overall identity
to a GDP/GTP exchange protein Rab3-GEP (4,
5). MADD is 87 identical to KIAA0358, a brain
protein of unknown function (4). Identification of
MADD as a component of the TNFR1 signaling
complex and the similarity between MADD and
Rab3-GEP provides a connection between
TNFR1 activation and downstream MAP kinase
activity through a guanine-nucleotide exchange
protein.
Specificity:
This antibody recognizes MADD.
Positive control: Whole cell lysate from HeLa or
NIH3T3 cells. 200 to 220 kDa bands should be
detected.
Species Reactivity:
Human and mouse, other species not tested.
Ig Isotype: Rabbit IgG
Immunogen:
A peptide corresponding to amino acids 1570 to
1588 of human MADD. The sequence of
immunogenic peptide is identical to that of
DENN and differs by one amino acid with rat
GDP/GTP exchange protein Rab3-GEP.
Format:
Purified IgG, 100 μg in 200 μl of PBS containing
0.02 sodium azide.
Storage and Stability:
Stable for at least one year when stored at 4°C.
Applications and Suggested Dilutions:

Western blot: Suggested dilution: 1:250 to
1:500.
The optimal dilution for a specific application
should be determined by the researcher.
Limitations:
For in vitro research use only. Not for use in
diagnostics or in humans.
Warranty:
No warranties, expressed or implied, are made
regarding the use of this product. KAMIYA
BIOMEDICAL COMPANY is not liable for any
damage, personal injury, or economic loss
caused by this product.